Selective BAFF blockade prevents the development of lupus nephritis in mice (43), and the humanized anti-BAFF IgG1 antibody belimumab is licensed for use in patients with SLE (44), with potential efficacy in lupus nephritis (45). This evidence concerns the gene TNFSF13B and lupus nephritis.